Abstract
Vaccination against melanoma has a long history but only recently has this therapeutic approach found a reliable scientific rationale. This review summarizes and updates the knowledge on the role of the main players in the vaccination strategy against metastatic melanoma, that is, the melanoma-associated antigens recognized by T and natural killer T lymphocytes, the conditions for the immune response to develop and the mechanisms that interfere with it. A commented list of the major vaccination trials whose results have been recently, published or are ongoing is also presented. Reasons for failure and potential success are underlined to offer a balanced view of this scientifically exciting but still clinically unrewarding field of investigation.
Original language | English |
---|---|
Pages (from-to) | 195-207 |
Number of pages | 13 |
Journal | Expert Review of Dermatology |
Volume | 3 |
Issue number | 2 |
DOIs | |
Publication status | Published - Apr 2008 |
Keywords
- Melanoma
- Melanoma vaccines
- Melanoma-associated antigens
- NKG2D
- T lymphocytes
- T-cell responses
ASJC Scopus subject areas
- Dermatology